Company intelligence / Profile preview

Copal International

Ownership: Private
Development stage: Other

Overview

Copal Scientific develops innovative biotechnology and nanotechnology solutions addressing challenges in human/animal health, agriculture, environmental sustainability. Their portfolio includes non-toxic antimicrobial bioproducts and custom-designed nanoparticles for sensing/material doping. They offer project-based research services but do not appear to have clinical trial results or marketed therapeutics.

Therapeutic areas: OtherInfectious Diseases
Modalities: BiologicNanoparticleSensor/deviceSmall molecule
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Copal International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Copal International.

Explore the full profile